Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VKTX
CUSIPN/A
Phone858-704-4660
Debt
Debt-to-Equity RatioN/A
Current Ratio12.44
Quick Ratio12.44
Price-To-Earnings
Trailing P/E Ratio-15.58
Forward P/E Ratio-27.36
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.38 per share
Price / Book32.39
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,570,000.00
Net MarginsN/A
Return on Equity-79.70%
Return on Assets-59.44%
Miscellaneous
Employees14
Outstanding Shares50,930,000
Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions
What is Viking Therapeutics' stock symbol?
Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."
How were Viking Therapeutics' earnings last quarter?
Viking Therapeutics Inc (NASDAQ:VKTX) announced its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.02. View Viking Therapeutics' Earnings History.
When is Viking Therapeutics' next earnings date?
What price target have analysts set for VKTX?
5 Wall Street analysts have issued 12-month price objectives for Viking Therapeutics' stock. Their forecasts range from $13.00 to $15.00. On average, they expect Viking Therapeutics' stock price to reach $14.25 in the next year. View Analyst Ratings for Viking Therapeutics.
Who are some of Viking Therapeutics' key competitors?
Some companies that are related to Viking Therapeutics include Evotec (EVTCY), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), Clovis Oncology (CLVS), PTC Therapeutics (PTCT), Xencor (XNCR), Enanta Pharmaceuticals (ENTA), Global Blood Therapeutics (GBT), TESARO (TSRO), Heron Therapeutics (HRTX), Spectrum Pharmaceuticals (SPPI), Puma Biotechnology (PBYI), Endo International (ENDP) and Insmed (INSM).
Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the folowing people:
- Dr. Brian Lian, Pres, CEO & Director (Age 52)
- Mr. Michael Morneau, CFO & Principal Accounting Officer (Age 53)
- Mr. Gregory S. Zante CPA, VP of Fin. & Operations (Age 47)
- Ms. Amy Broidrick, Sr. VP of Corp. Devel.
- Dr. Hiroko Masamune Ph.D., Sr. VP of Pharmaceutical Devel. (Age 61)
When did Viking Therapeutics IPO?
(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.
Has Viking Therapeutics been receiving favorable news coverage?
News articles about VKTX stock have trended positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Viking Therapeutics earned a news sentiment score of 0.34 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.44 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Viking Therapeutics' major shareholders?
Viking Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sphera Funds Management LTD. (3.13%), Millennium Management LLC (2.75%), Sio Capital Management LLC (2.51%), Opaleye Management Inc. (2.16%), Victory Capital Management Inc. (1.19%) and Park West Asset Management LLC (0.98%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Matthew W Foehr and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.
Which major investors are selling Viking Therapeutics stock?
Which major investors are buying Viking Therapeutics stock?
VKTX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Opaleye Management Inc., Victory Capital Management Inc., BlackRock Inc., Iguana Healthcare Management LLC, Tibra Equities Europe Ltd, Spark Investment Management LLC and Trexquant Investment LP. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton, Lawson Macartney and Matthew W Foehr. View Insider Buying and Selling for Viking Therapeutics.
How do I buy shares of Viking Therapeutics?
Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viking Therapeutics' stock price today?
One share of VKTX stock can currently be purchased for approximately $12.31.
How big of a company is Viking Therapeutics?
Viking Therapeutics has a market capitalization of $634.63 million. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 14 workers across the globe.
How can I contact Viking Therapeutics?
Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]
MarketBeat Community Rating for Viking Therapeutics (VKTX)
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
